Advances in nanotechnology-based platforms for survivin-targeted drug discovery.

George, Rosemol; Hehlgans, Stephanie; Fleischmann, Maximillian; Rödel, Claus; Fokas, Emmanouil; Rödel, Franz

George, Rosemol; Hehlgans, Stephanie; Fleischmann, Maximillian; Rödel, Claus; Fokas, Emmanouil; Rödel, Franz.

Afiliação

George R; Department of Radiotherapy and Oncology, Goethe University, Frankfurt am Main, Germany.
Hehlgans S; Department of Radiotherapy and Oncology, Goethe University, Frankfurt am Main, Germany.
Fleischmann M; Department of Radiotherapy and Oncology, Goethe University, Frankfurt am Main, Germany.
Rödel C; Department of Radiotherapy and Oncology, Goethe University, Frankfurt am Main, Germany.
Fokas E; Department of Radiotherapy and Oncology, Goethe University, Frankfurt am Main, Germany.
Rödel F; Department of Radiotherapy and Oncology, Goethe University, Frankfurt am Main, Germany.

Expert Opin Drug Discov ; 17(7): 733-754, 2022 07.

Article em En | MEDLINE | ID: mdl-35593177

Assuntos

Nanopartículas; Neoplasias; Sistemas de Liberação de Medicamentos; Descoberta de Drogas; Humanos; Nanomedicina; Nanotecnologia; Neoplasias/patologia; Survivina/uso terapêutico

Palavras-chave

Survivin; cancer; molecular targeting; nanoparticles; nanotechnology

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nanopartículas / Neoplasias Limite: Humans Idioma: En Revista: Expert Opin Drug Discov Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google